<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-18 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-18</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-18</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-94cd007963af95fe925e94b67d03d5e28b01bd3e</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/94cd007963af95fe925e94b67d03d5e28b01bd3e" target="_blank">Advances in targeted therapy and immunotherapy for melanoma (Review)</a></p>
                <p><strong>Paper Venue:</strong> Experimental and Therapeutic Medicine</p>
                <p><strong>Paper TL;DR:</strong> A review of clinical trials of the application of targeted therapy and immunotherapy, as well as novel approaches of their combinations for the treatment of metastatic melanoma in recent years, with a focus on upcoming initiatives to improve the efficacy of these treatment approaches.</p>
                <p><strong>Paper Abstract:</strong> Melanoma is the most aggressive and deadly type of skin cancer and is known for its poor prognosis as soon as metastasis occurs. Since 2011, new and effective therapies for metastatic melanoma have emerged, with US Food and Drug Administration approval of multiple targeted agents, such as V-Raf murine sarcoma viral oncogene homolog B1/mitogen-activated protein kinase kinase inhibitors and multiple immunotherapy agents, such as cytotoxic T lymphocyte-associated protein 4 and anti-programmed cell death protein 1/ligand 1 blockade. Based on insight into the respective advantages of the above two strategies, the present article provided a review of clinical trials of the application of targeted therapy and immunotherapy, as well as novel approaches of their combinations for the treatment of metastatic melanoma in recent years, with a focus on upcoming initiatives to improve the efficacy of these treatment approaches for metastatic melanoma.</p>
                <p><strong>Cost:</strong> 0.034</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e18.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e18.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801 (neoadjuvant vs adjuvant pembrolizumab trial)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized phase II trial comparing neoadjuvant-plus-adjuvant pembrolizumab versus adjuvant-only pembrolizumab in resectable high-risk melanoma; reported a large improvement in event-free survival with neoadjuvant exposure.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>SWOG S1801 (neoadjuvant vs adjuvant pembrolizumab)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase II randomized (neoadjuvant-plus-adjuvant vs adjuvant-only pembrolizumab)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant pembrolizumab followed by surgery then adjuvant pembrolizumab vs upfront surgery followed by adjuvant pembrolizumab (adjuvant-only).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable stage IIIB–IIID/IV melanoma (as reported in the paper: resectable high-risk patients)</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage IIIB–IIID/IV (paper statement); exact enrollment criteria not listed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pembrolizumab (single-agent); exact dose/schedule not specified in this review article.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant pembrolizumab after surgery (both arms received adjuvant pembrolizumab per study design).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Upfront surgery followed by adjuvant pembrolizumab (no neoadjuvant exposure).</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Event-free survival (EFS) at 2 years reported in review; other endpoints not detailed in this review.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>Reported 2-year EFS 72% in neoadjuvant arm vs 49% in adjuvant-only arm; described as a 42% reduction in 2-year event-free survival risk favoring neoadjuvant (review gives absolute rates but not HR/CIs).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>2-year EFS absolute difference reported: +23 percentage points (72% vs 49%).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>The review states that neoadjuvant therapy may induce a deeper immune response because the tumor is present during initial therapy (mechanistic rationale summarized by authors).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>This review provides summary results but does not include full trial details (sample size, HRs, CIs, detailed safety), limiting ability to fully evaluate bias and statistical robustness.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in targeted therapy and immunotherapy for melanoma (Review)', 'publication_date_yy_mm': '2023-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e18.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e18.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN (neoadjuvant vs adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized Phase Ib trial comparing neoadjuvant ipilimumab+nivolumab versus adjuvant ipilimumab+nivolumab in patients with macroscopic stage III melanoma; demonstrated high pathologic response rates with neoadjuvant dosing but very high grade 3–4 toxicity in the initial schedule.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>OpACIN: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Blank et al., Nat Med 2018 (as cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2018</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase Ib randomized (neoadjuvant vs adjuvant)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Arm A: Adjuvant ipilimumab + nivolumab (four cycles every 3 weeks after therapeutic lymph node dissection). Arm B: Neoadjuvant ipilimumab + nivolumab (two cycles every 3 weeks before surgery with TLND at week 6) followed by two cycles postoperatively at week 12.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic stage III melanoma (20 participants in the trial as reported by the review).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III melanoma with nodal disease (therapeutic lymph node dissection planned).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>20</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Approximately 10 per arm (total n=20 as reported).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab plus nivolumab (initially ipilimumab 3 mg/kg + nivolumab 1 mg/kg regimen as used in early studies though exact dosing scheme is described in original OpACIN publication; review describes 2 cycles neoadjuvant every 3 weeks).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Two cycles of combination given every 3 weeks before surgery; TLND planned at week 6; two further cycles given postoperatively at week 12.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant ipilimumab + nivolumab (four cycles starting after surgery in adjuvant arm); in neoadjuvant arm two additional cycles postoperatively.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Upfront surgery followed by four cycles of adjuvant ipilimumab+nivolumab.</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td>Surgery at week 6 in neoadjuvant arm (per protocol described in review).</td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Not reported as a problem in review; surgery was performed per protocol at week 6 in neoadjuvant arm.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Pathologic partial response (PPR) reported as 78% in the neoadjuvant arm (review uses term PPR; exact pCR/MPR definitions in trial publication).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Review reports that responding patients (pathologic responders) remained free of relapse at 2 years in the neoadjuvant arm.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response, relapse-free survival (follow-up ~25.6 months), toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Responding patients in neoadjuvant arm remained free of relapse at 2 years (review statement).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Median follow-up reported in review ~25.6 months for OpACIN neoadjuvant arm.</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>The trial motivated later translational work; review emphasizes high pathologic response and links to later OpACIN-neo biomarker analyses (IFN-γ score, TMB).</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors argued that neoadjuvant exposure produced unexpectedly high pathologic response rates and durable RFS, supporting the hypothesis that treating with tumor in place enhances systemic anti-tumor immunity (review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Very high: ~90% of patients experienced one or more grade 3 or 4 immune-related adverse events in both arms (review reports ~90%), leading to early discontinuation in 18/20 patients.</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td>High early treatment discontinuation due to toxicity (18 of 20 patients had early discontinuation per review).</td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Not reported as a major issue in review; main concern was systemic toxicity rather than surgical delay.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Small sample size (n=20), high toxicity limiting feasibility of initial dosing schedule; results motivated optimization in OpACIN-neo.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in targeted therapy and immunotherapy for melanoma (Review)', 'publication_date_yy_mm': '2023-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e18.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e18.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo (neoadjuvant ipilimumab + nivolumab dosing optimization)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multicentre phase II randomized trial testing three neoadjuvant dosing schedules of ipilimumab + nivolumab in resectable stage III melanoma; identified a tolerable effective regimen with high pathologic response and lower severe toxicity, and provided translational biomarker correlates (IFN-γ score, TMB) predictive of pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule for neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>OpACIN-neo: Identification of optimal neoadjuvant ipilimumab + nivolumab dosing schedule in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Lancet Oncol 2019 (as cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicentre Phase II randomized (three neoadjuvant dosing schedules), translational correlative analyses included</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Three different neoadjuvant dosing regimens of ipilimumab + nivolumab were compared to identify a tolerable/effective schedule; therapeutic lymph node dissection planned at week 6 without additional adjuvant therapy as part of dose-finding strategy.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with macroscopic stage III melanoma (n=86 enrolled and randomized as reported in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III melanoma; TLND planned at week 6.</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>86</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Randomized across three dosing cohorts; exact per-cohort numbers not stated in review.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Multiple dosing regimens tested; tolerable identified regimen was two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/kg every 3 weeks (neoadjuvant).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Two cycles over ~6 weeks; surgery (TLND) at week 6.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>In the OpACIN-neo trial as described, no additional adjuvant therapy was given as part of the primary protocol (TLND at week 6 without additional adjuvant therapy in the trial design described in review).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td>Surgery at week 6 after neoadjuvant dosing (per protocol in review).</td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>No surgery feasibility problems reported in review; surgical plan executed at week 6.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Review reports a high pathologic partial/major response (PPR/MPR) rate of 77% with the identified tolerable regimen; exact pCR vs MPR split not specified in review.</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>After median follow-up of 4 years OpACIN and OpACIN-neo showed durable RFS in >80% of patients; pathologic response correlated strongly with improved RFS (review states pathologic response appears to be a surrogate of long-term benefit).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates, grade 3/4 irAEs, relapse-free survival (RFS) with follow-up up to 4 years, translational biomarker analyses.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Review states that >80% of patients had durable RFS after median follow-up of 4 years; updated OpACIN-neo estimated 3-year RFS 95% for pathologic responders vs 37% for non-responders.</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>OpACIN-neo: estimated 3-year RFS 95% in pathologic responders vs 37% in non-responders (absolute difference reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Median follow-up ~4 years for OpACIN-neo; other OpACIN update median follow-up 69 months for OpACIN (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Robust translational correlates reported: high baseline IFN-γ gene expression score and high tumor mutational burden (TMB) associated with markedly higher pathologic response rates; pathologic response strongly associated with long-term RFS.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td>High IFN-γ score in tumor associated with pathologic response; review states IFN-γ signature and TMB were predictive of pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td>High IFN-γ gene expression score and high tumor mutational burden (TMB) predicted pathologic response: PPR 100% for high IFN-γ + high TMB; PPR 39% for low IFN-γ + low TMB; single-high groups had 91% and 88% respectively (numbers reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors and reviewers claim neoadjuvant exposure while tumor is present expands/boosts anti-tumor immunity leading to high pathologic responses and durable RFS; IFN-γ signaling and high neoantigen load (TMB) underpin responsiveness.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>With the selected tolerable regimen (ipilimumab 1 mg/kg + nivolumab 3 mg/kg x2) grade 3–4 irAEs were ~20% as reported in the review (much lower than original OpACIN schedule).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Not reported as major issue in review; main concerns were systemic irAEs which were reduced with optimized dosing.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td>Biomarker-defined subgroups (IFN-γ score, TMB) were strongly associated with pathologic response; no other subgroup interaction p-values provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>PRADO subsequent data showed that pathologic partial responses (PPR) may not uniformly predict the same durable RFS across cohorts (see PRADO entry); thus pathologic response definitions and their predictive value may vary between studies.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>OpACIN-neo was relatively small (n=86), open-label, and used pathologic response as a surrogate—longer follow-up and randomized phase III confirmation required; cohort heterogeneity across trials affects direct comparisons.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in targeted therapy and immunotherapy for melanoma (Review)', 'publication_date_yy_mm': '2023-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e18.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e18.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PRADO (OpACIN-neo extension)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PRADO (Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab + nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Multi-center phase II extension cohort of OpACIN-neo testing a pathologic response-driven surgical and adjuvant approach after neoadjuvant ipilimumab+nivolumab in stage IIIB–D nodal melanoma, evaluating feasibility of de-escalating surgery and personalizing adjuvant therapy based on response.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>PRADO: Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab + nivolumab in high-risk stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>PRADO (OpACIN-neo extension cohort)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Reijers et al., Nat Med 2022 (as cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Multicentre phase II extension (pathologic response-driven surgical/adjuvant strategy after neoadjuvant ipilimumab+nivolumab).</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>All patients received neoadjuvant ipilimumab + nivolumab for 6 weeks; subsequent management depended on index node pathology: MPR (≤10% viable tumor) omitted TLND and adjuvant therapy; PPR (>10–≤50% viable) underwent TLND only; PNR (>50% viable) underwent TLND plus adjuvant therapy (nivolumab for BRAF wild-type or BRAF/MEK for BRAF-mutant).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage IIIB–IIID nodal melanoma (n=99 in PRADO cohort reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>IIIB–IIID nodal melanoma (macroscopic nodal disease).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Allocation into response-based management groups post-neoadjuvant: numbers per response group not explicitly stated in review.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab + nivolumab for 6 weeks (neoadjuvant).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>6 weeks total (regimen consistent with two cycles before surgery).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Varied by pathologic response: none for MPR (≤10% viable in index node), TLND only for PPR, TLND + adjuvant (nivolumab or dabrafenib+trametinib) for PNR.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td>Surgery planned after 6 weeks of neoadjuvant therapy (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Not reported as a major issue; trial focused on whether TLND could be omitted safely in MPR patients.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>MPR defined as ≤10% viable tumor in index node; PPR defined as >10% to ≤50% viable tumor; PNR defined as >50% viable tumor (definitions stated in review).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>PRADO findings showed discordance vs OpACIN-neo: patients with PPR in PRADO had lower 2-year RFS (64%) compared to 4-year RFS 100% reported for PPR in OpACIN-neo, raising concerns on generalizability of pathologic response as surrogate. MPR patients had 2-year RFS 93%; PNR 71% (review reported).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response categories, 2-year RFS rates by response group, feasibility of response-directed surgery/adjuvant approach.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>Reported 2-year RFS: PPR 64% (in PRADO), MPR 93%, PNR 71% (as reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>2-year RFS by pathologic category given above (absolute rates presented).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>2-year RFS reported; median follow-up not specifically stated in review for PRADO cohort.</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>PRADO results raised caution that pathologic response metrics need careful validation as surrogates; translational correlates not detailed in the review for PRADO beyond response-driven outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Review highlights that PRADO data prompted questions about whether MPR (≤10% viable tumor) may be a better predictor than broader definitions like PPR; emphasizes need for standardized pathologic definitions and validation.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Not reported as a limiting issue in review; focus was on oncologic outcomes of de-escalated surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td>Outcome differences by pathologic responder group (MPR/PPR/PNR) described; no interaction p-values provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>PRADO produced somewhat lower RFS for PPR patients compared with OpACIN-neo, serving as potential counterevidence to generalizing pathologic partial response as uniformly predictive across cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Non-randomized response-directed management within extension cohort; potential selection and historical comparison biases when contrasted with OpACIN-neo; limited follow-up for some groups.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in targeted therapy and immunotherapy for melanoma (Review)', 'publication_date_yy_mm': '2023-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e18.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e18.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Neoadjuvant relatlimab+nivolumab</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Neoadjuvant relatlimab plus nivolumab in resectable melanoma (small neoadjuvant+adjuvant trial)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Small neoadjuvant + adjuvant trial of relatlimab (anti-LAG-3) combined with nivolumab in resectable clinical stage III/oligometastatic stage IV melanoma showing high major pathologic response rate and promising RFS among responders with favorable neoadjuvant safety.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant relatlimab and nivolumab in resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Amaria et al., Nature 2022 (as cited in review ref 126)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Small prospective neoadjuvant + adjuvant cohort (single-arm) with translational endpoints</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Two neoadjuvant doses of relatlimab 160 mg + nivolumab 480 mg every 4 weeks followed by surgery then up to 10 adjuvant doses of combination therapy (single-arm design reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable clinical stage III or oligometastatic stage IV melanoma; small cohort (n=30 reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage III or oligometastatic stage IV melanoma (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>30</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Single-arm (n=30).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Relatlimab 160 mg + nivolumab 480 mg administered every 4 weeks for 2 cycles prior to surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>2 neoadjuvant doses over 8 weeks (every 4 weeks), then surgery, then adjuvant therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Up to 10 doses of adjuvant relatlimab + nivolumab (per protocol in the small trial reported).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>No major neoadjuvant surgical safety problems reported in review; neoadjuvant safety favorable with no grade 3/4 irAEs during neoadjuvant window.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Major pathologic response (MPR) rate reported as 57% (review statement).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Patients achieving any pathologic response had very favorable 1- and 2-year RFS (100% and 92% respectively) compared to those without pathologic response (review reports these numbers).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>MPR rate, 1- and 2-year RFS in responders, safety (neoadjuvant and adjuvant).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td>1- and 2-year RFS for patients achieving any pathologic response reported as 100% and 92%, respectively (review).</td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>RFS timepoint rates reported above for pathologic responders.</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Review suggests neoadjuvant relatlimab+nivolumab produced high MPR and improved RFS in pathologic responders, supporting the concept that neoadjuvant checkpoint blockade enhances systemic anti-tumor immunity when tumor is present.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>No grade 3 or 4 immune-related adverse events occurred during the neoadjuvant window; 26% grade 3/4 toxicities observed in the adjuvant phase (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Neoadjuvant safety favorable with no grade 3/4 irAEs pre-surgery per review; surgical complications not highlighted as problematic.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>Small sample size (n=30) noted in review as limitation; results consistent with OpACIN-neo arms but require larger confirmatory trials.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Small, non-randomized, limited follow-up; findings encouraging but preliminary and not definitive for comparative efficacy vs adjuvant-only approaches.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in targeted therapy and immunotherapy for melanoma (Review)', 'publication_date_yy_mm': '2023-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e18.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e18.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NADINA</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NADINA (Randomized phase 3 trial comparing neoadjuvant ipilimumab + nivolumab vs adjuvant nivolumab in macroscopic resectable stage III melanoma)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Planned/ongoing phase III randomized trial to compare neoadjuvant ipilimumab+nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma, using pathologic response-informed adjuvant strategies in some arms per amendment.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>NADINA: Phase 3 randomized trial of neoadjuvant ipilimumab+nivolumab vs adjuvant nivolumab in resectable stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>NADINA (J Clin Oncol TPS9605 referenced)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Lucas et al., J Clin Oncol 2022 (trial protocol/abstract cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase III randomized (ongoing at time of review) with response-driven amendments</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Arm A: Neoadjuvant ipilimumab + nivolumab with response-driven surgery/adjuvant strategy (MPR patients receive 2 cycles and TLND at week 6 etc.). Arm B: Upfront TLND followed by adjuvant nivolumab (standard adjuvant-only comparator).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Macroscopic resectable stage III melanoma (trial entry criteria as per protocol; review describes macroscopic stage III patients).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic resectable stage III (per review and trial protocol abstract).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab + nivolumab neoadjuvant (specific dosing per trial protocol; review describes 2 cycles for MPR patients in amended design).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Amended design: MPR patients receive two cycles then TLND at week 6; others managed according to path response (per review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant nivolumab in the adjuvant-only arm; in neoadjuvant arm adjuvant therapy depended on pathologic response per amendment.</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Standard adjuvant nivolumab after upfront TLND.</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td>TLND at week 6 for neoadjuvant MPR patients in amended design; details per protocol.</td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Trial amendment uses MPR (≤10% viable tumor) to guide omitting TLND in some patients (per review description).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Trial planned to compare RFS/EFS between neoadjuvant and adjuvant strategies (design described in review); results pending.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Trial design and amendments reflect mechanistic hypothesis that pathologic response after neoadjuvant therapy can guide de-escalation and that neoadjuvant exposure may improve systemic immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Ongoing trial at time of review; no results to evaluate; amendments reflect evolving understanding which may complicate interpretation.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Advances in targeted therapy and immunotherapy for melanoma (Review)', 'publication_date_yy_mm': '2023-07'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <em>(Rating: 2)</em></li>
                <li>Identification of the optimal combination dosing schedule for neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial. <em>(Rating: 2)</em></li>
                <li>Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <em>(Rating: 2)</em></li>
                <li>Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial. <em>(Rating: 2)</em></li>
                <li>Neoadjuvant relatlimab and nivolumab in resectable melanoma. <em>(Rating: 2)</em></li>
                <li>SWOG S1801 <em>(Rating: 2)</em></li>
                <li>The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma. <em>(Rating: 2)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>